Danish biotech Samplix raises €25M first close to scale antibody discovery
Danish BioTech Samplix secures €25 million in first close of financing round to scale antibody discovery
AI Overview
Samplix, a Danish biotech company, announced a €25 million first close of its financing round.
Why it matters
The funding breakdown and the incoming board member from Evotec show how a single-cell screening platform is being positioned for AI-driven drug discovery data needs.